Clinical Trial: Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07679841) titled 'Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients' on June 15.

Brief Summary: COLOMBE is a multicenter, single arm, phase 1/2 trial designed to evaluate the safety and efficacy of imiquimod cream with IV low dose nivolumab in primary resectable vulvar squamous cell carcinoma patients prior to surgery, leveraging the preoperative "window of opportunity" period, an unavoidable interval due to surgical scheduling.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Vulvar Squamous Cell Carcinoma

Intervention: DRUG: Imiquimod 5% cream

At the starting dose (DL1) : ...